True Resistant Hypertension Following Observed Drug Ingestion: A Systematic Evaluation
File(s)
Author(s)
Type
Journal Article
Abstract
The authors investigated the role of poor drug adherence in treatment-resistant hypertension following observed drug ingestion in 102 patients. Median blood pressures (BPs) were 170/91 mm Hg at referral, 153/84 mm Hg prior to, and 142/79 mm Hg during a 4- to 6-hour period after drug ingestion. Median daytime ambulatory BP monitoring (ABPM) over the following 24 hours was 142/80 mm Hg. Median BP at a final follow-up clinic visit was 147/79 mm Hg. The cumulative number of patients achieving a goal of <140/90 mm Hg in clinic or <135/85 mm Hg mean on ABPM was 57 (56%), with a further nine (9%) controlled at the final follow-up clinic visit. Thus, 65% of patients achieved a systolic BP <140 mm Hg at any point immediately prior to, or after, drug ingestion; the residual 35% were considered to have true resistant hypertension. In conclusion, among patients with suspected resistant hypertension, a minority were truly treatment-resistant following observed drug ingestion and BP monitoring.
Date Issued
2016-08-20
Date Acceptance
2016-07-23
Citation
Journal of Clinical Hypertension, 2016, 19 (3), pp.250-255
ISSN
1751-7176
Publisher
Wiley
Start Page
250
End Page
255
Journal / Book Title
Journal of Clinical Hypertension
Volume
19
Issue
3
Copyright Statement
This is the peer reviewed version of the following article: J Clin Hypertens (Greenwich). 2017;19:250–255. 10.1111/jch.12896 © 2016 Wiley Periodicals, Inc., which has been published in final form at https://dx.doi.org/10.1111/jch.12896. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.
Sponsor
National Institute for Health Research
Imperial College Healthcare NHS Trust- BRC Funding
National Institute for Health Research
Grant Number
NF-SI-0510-10055
RDC02 79560
NF-SI-0513-10059
Subjects
Science & Technology
Life Sciences & Biomedicine
Peripheral Vascular Disease
Cardiovascular System & Cardiology
RENAL DENERVATION
CONTROLLED-TRIAL
BLOOD-PRESSURE
SPIRONOLACTONE
STATEMENT
1101 Medical Biochemistry And Metabolomics
1102 Cardiovascular Medicine And Haematology
1103 Clinical Sciences
Cardiovascular System & Hematology
Publication Status
Published